This study used data from COVID-19 patients hospitalized at 28 centers, representing 13 countries and four continents, to describe and assess the incidence of neurological manifestations associated with a COVID-19 diagnosis. The study population was derived from three different cohorts: the GCS-NeuroCOVID all COVID-19 cohort (N=3055) included COVID-19 patients with and without neurological manifestations; the GCS-NeuroCOVID COVID-19 neurological cohort (N=475) included COVID-19 patients hospitalized in the US with neurological manifestations; and the ENERGY cohort (N=214) included hospitalized COVID-19 patients who received formal neurological consultation. Overall, 82% of the total study populations experienced any neurological manifestations. The most common self-reported neurological manifestation was headache, reported by 38%, 35%, and 27% of patients in these cohorts, respectively. This was followed by anosmia or ageusia which was reported by 26% of patients across all three cohorts. The most common clinically captured neurological sign was acute encephalopathy which was experienced by nearly half of all participants, followed by coma (17%), and stroke (3%). Patients with clinically captured neurological signs had dramatically higher odds for in-hospital death (aOR 5.99, 95% CI 4.33 – 8.28). Given the high incidence of neurological manifestations of COVID-19, further research is warranted to understand their mechanisms of action and long-term outcomes.